Sponsor:
Genelux Corporation
Code:
NCT06463665
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer
Advanced Squamous Non-Small Cell Lung Carcinoma
Metastatic Non-squamous Non Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Olvimulogene nanivacirepvec
Platinum chemotherapy: carboplatin or cisplatin
Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
Docetaxel
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Genelux Corporation on 2025-04-23.